346 related articles for article (PubMed ID: 27940327)
1. Peptide vaccines in cancer-old concept revisited.
Kumai T; Kobayashi H; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Apr; 45():1-7. PubMed ID: 27940327
[TBL] [Abstract][Full Text] [Related]
2. Synthetic peptides as cancer vaccines.
Sundaram R; Dakappagari NK; Kaumaya PT
Biopolymers; 2002; 66(3):200-16. PubMed ID: 12385038
[TBL] [Abstract][Full Text] [Related]
3. How much help does a vaccine-induced T-cell response need?
Weber JS; Mulé JJ
J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
[No Abstract] [Full Text] [Related]
4. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
5. [Peptide-based vaccine therapy for cancer patients].
Yamada A
Nihon Rinsho; 2005 Apr; 63 Suppl 4():602-7. PubMed ID: 15861717
[No Abstract] [Full Text] [Related]
6. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
8. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
9. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.
Hevey R; Ling CC
Future Med Chem; 2012 Mar; 4(4):545-84. PubMed ID: 22416779
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: of trials and T cells.
Harv Health Lett; 1999 Jul; 24(9):4-5. PubMed ID: 10368532
[No Abstract] [Full Text] [Related]
12. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
13. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
14. Peptide-based anticancer vaccines: recent advances and future perspectives.
Mocellin S; Pilati P; Nitti D
Curr Med Chem; 2009; 16(36):4779-96. PubMed ID: 19929787
[TBL] [Abstract][Full Text] [Related]
15. Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses.
Vermaelen K
Front Immunol; 2019; 10():8. PubMed ID: 30723469
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
17. Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.
Fernández A; Oliver L; Alvarez R; Fernández LE; Lee KP; Mesa C
Hum Vaccin Immunother; 2014; 10(11):3251-60. PubMed ID: 25483674
[TBL] [Abstract][Full Text] [Related]
18. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
